Heparins are are sulfated polysaccharides that have tremendous clinical importance as anticoagulant drugs. Monitoring of heparin blood levels can improve patient safety. In clinical practice, heparins are monitored indirectly by their inhibtory effect on coagulation proteases.
Introduction
Heparins are widely used clinical anticoagulants, about one billion doses are applied each year. Heparin is a linear, polydisperse polysaccharide consisting of disaccharide repeating units (scheme 1) and has a high negative charge density due to sulfation. Unfractionated heparin (mean molecular weight between 13000 and 15000) is clinically applied since the 1930s. For many indications, there has been a trend towards use of fractionated low molecular weight heparins (mean molecular weight between 4000 and 7000), manufactured by partial depolymerisation of unfractionated heparin. Low-molecular-weight heparins, such as the most widely used enoxaparin, have lower side effects and a more favourable pharmacokinetics. Safe and effective use of heparins requires maintaining a delicate balance -dosing low enough to minimize the risk of bleeding, yet high enough to treat or prevent thrombosis. Measurement of activated partial thromboplastin time aPTT (the ability to delay clotting) and chromogenic anti-factor Xa assay (inhibition of a specific blood coagulation factor), are the currently accepted practice for laboratory monitoring of unfractionated and low molecular weight heparins, respectively, in patients' blood. Accurate laboratory monitoring has proven to be difficult to achieve. [1] [2] [3] Comparability between commcercially available anti-factor Xa assays is poor. Scheme 1. Structure of the major repeating disaccharide unit of heparin.
The drawbacks of the established indirect assays have stimulated the development of direct optical detection methods that rely on the color or fluorescence change of cationic dyes upon binding to polyanionic heparin [4] . Only few such dyes or assay kits, however, are commercially and widely available to reserachers and clinicians.
This study compares the performance of three commercial dyes (assays, respectively) for direct heparin detection in human plasma: The more recently developed fluorescent dye Heparin Red and the traditional metachromatic dyes Azure A and Toluidine Blue.
Heparin Red is a polyamine-functionalized, red-fluorescent perylene diimide (scheme 2). It forms a supramolecular complex with polyanionic polysaccharides in which aggregation of dye molecules results in contact quenching of fluorescence (scheme 3). [5] Strong binding of the polycationic probe to polyanionic heparin appears to be controlled by both electrostatic and aromatic pi-stacking interactions, with formation of charge-neutral aggrgeates. [6] The commercial Heparin Red Kit has been applied to the quantification in the low µg/mL range of unfractionated heparin [7] , the low molecular weight heparins enoxaparin [7] and dalteparin [8] , heparin octa-and decasacchairides [7] , chemically modified heparins [7] , heparan sulfate [9] , fucoidans [10] , carrageenan [8] , ulvan [8] , dextran sulfate [8] and sulfated hyaluronic acid [8] in human plasma. Heparin Red is used in several drug development projects for pharmacokinetic studies of non-anticoagulant heparins. [11] Heparin Red Azure A Toluidine Blue Scheme 2. Molecular structures of the polycationic, fluorescent probe Heparin Red, and the monocationic, metachromatic dyes Azure A and Toluidine Blue. Azure A and Toluidine Blue (scheme 2) are blue, monocationic dyes of the thiazine family.
These dyes show metachromatic behaviour in the presence of sulfated polysaccharides [12, 13] [17] [18] [19] [20] . In blood plasma, strong matrix interference complicates the detection of heparin. Only few protocols for the direct determination of unfractionated heparin in plasma or serum samples have been described in the literature. [21] [22] [23] The present study compares the performance and sensitivity of the three commercial dyes Heparin Red, Azure A and Toluidine Blue, using the same heparin-spiked plasma samples and a convenient, mix-and-read microplate protocol.
Materials and Methods

Instrumentation
Absorbance measurements 
Reagents
Dyes and Kits
The 14190-094 was purchased from Thermo Fisher Scientific.
Methods
Heparin Red® Kit
For determination of heparin concentrations in the range <1 IU/mL in in plasma samples, the protocol of the provider for a 96-well microplate assay was followed. A mixture of 100 µL
Heparin Red solution and 9 mL Enhancer solution was freshly prepared. 20 µL of the heparin spiked plasma sample was pipetted into a microplate well, followed by 80 µl of the Heparin
Red -Enhancer mixture. The microplate was introduced in the fluorescence reader and shaken for 3 minutes, using plate shaking function of the reader (setting "high"), followed by fluorescence measurement within 1 minute. For determination of heparin concentrations up to 10 IU/mL in plasma samples, a mixture of 600 µL Heparin Red solution and 9 mL
Enhancer solution was freshly prepared. Otherwise, the protocol was followed as described above.
Azure A assay, method 1
For determination of heparin concentrations in plasma samples, the literature protocol [21] for a "4-units assay" was followed, but heparin from porcine mucosa (instead of bovine lung heparin) was used and the protocol adapted for detection in 96-well microplates. A solution of Azure A in water (8 mg / 100 mL, c = 80µg/mL) was freshly prepared. 50 µL of the heparin spiked plasma sample was pipetted into a microplate well, followed by 50 µl of the Azure A solution. The microplate was immediately introduced in the absorbance reader and shaken for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by absorbance measurement within 1 minute.
Azure A assay, method 1a
For determination of heparin concentrations in plasma samples, the literature protocol [21] for a "10-units assay" was followed, but heparin from porcine mucosa (instead of bovine lung heparin) was used and the protocol adapted for detection in 96-well microplates. A solution of Azure A in water (1 mg / 100 mL, c = 10µg/mL) was freshly prepared. 10 µL of the heparin spiked plasma sample was pipetted into a microplate well, followed by 200 µl of the Azure A solution. The microplate was immediately introduced in the absorbance reader and shaken for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by absorbance measurement within 1 minute.
Azure A assay, method 2
For determination of heparin concentrations in plasma samples, a protocol described in a patent [22] was followed, but the commercial Azure A sample was not purified, human plasma was used (instaed of horse serum) and the protocol adapted for detection in 96-well microplates. A solution of Azure A (14.6 µg / mL) in 1% aqueous Pluronic (commercial product was diluted 10-fold with water) was freshly prepared. 10 µL of the heparin spiked plasma sample was pipetted into a microplate well, followed by 100 µl of the Azure A solution. The microplate was immediately introduced in the absorbance reader and shaken for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by absorbance measurement within 1 minute.
Toluidine Blue assay
For determination of heparin concentrations in plasma samples, a literature protocol [23] was followed, but sodium heparin (instead of lithium heparin) and citrated human plasma (instead of EDTA human plasma) were used and the protocol adapted for detection in 96-well microplates. A solution of Toluidine Blue (100 µg / mL) in phosphate buffered saline (DPBS) was freshly prepared. 50 µL of the heparin spiked plasma sample was pipetted into a microplate well, followed by 50 µl of the Toluidine Blue solution. The microplate was immediately introduced in the absorbance reader and shaken for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by absorbance measurement within 1 minute.
Preparation of spiked plasma samples
Plasma samples containing defined concentrations of heparins were prepared as follows:
Aqueous solutions (10 vol%) of unfractionated heparin and enoxaparin, respectively, were added too pooled human plasma to achieve a concentration of 10 IU/mL. Heparin concentrations required for the detections were adjusted by further dilution of this 10 IU/mL stock solution with the same plasma. The spiked plasma samples were stored at -20°C and thawed at room temperature before use.
Data analysis
Data were analyzed using Excel (Microsoft Office 10). Linear regression "through origin" ( with y-intercept set to 1) was applied to the response curves in figure 2 . Coefficients of determination (R 2 ) in table 1 were determined by linear regression.
Results and discussion
While the Heparin Red, Azure A and Toluidine Blue assay actually determine a mass concentration of heparin (the "chemical" heparin) rather than a biological activity, we refere in this work to IU (international units) of heparin for better comparability with published data for the metachromatic dyes and clinically relevant heparin levels. The heparin batch used in this work had a potency of 210 IU/mg solid, i.e. 1 IU corresponds to 4,8 µg.
The Heparin Red Kit was applied either as suggested by the protocol of the supplier, or adapted to higher heparin levels by using a higher concentrations of the dye (see "Materials and Methods" for details). For Azure A, we compared three different published protocols (method 1, 1a and 2) for heparin detection. In method 1 and 1a [21] , an aqueous solution of the dye and the heparin containing plasma sample are mixed in either a 1:1 ratio (for heparin levels up to 4 IU/mL, method 1) or 1:9 ratio (for heparin levels up to 10 IU/mL, method 1a) in a cuvette and dye absorbance at 620 nm is measured with a photometer. Azure A, Method 2, was described in a patent [22] : an aqueous solution of the dye containing an anionic surfactant is mixed with a heparin containing sample of horse serum at a 10:1 ratio in a cuvette and the absorbance spectrum recorded with a photometer. A protocol using Toluidine Blue [23] suggests mixing of equal amounts of a dye solution in phosphate buffered saline and heparin containing plasma sample, followed by absorbance readout with a Nanodrop photometer at 630 nm.
We adapted these protocols for microplates, i.e. dye solution and plasma sample were mixed 
Quantification of unfractionated heparin and enoxaparin at concentrations <1 IU/mL in human plasma
In the vast majority of clinical heparin applications, the recommended plasma level is < 1 IU/mL. More precisely, the range for therapeutic dosing is 0. IU/mL for Toluidine Blue [23] . Azure A, method 2, described in a patent [22] , claims a detection limit of 0.1 IU/mL heparin in horse serum, derived from changes in the area under the absorption spectra. In our hands, however, this protocol has the poorest detection limit and linearity (table 1) of all methods when applied to heparin-containing plasma samples in a microplate, independent of how the optical signal change is monitored. The detection and quantification limits of the assays (table 1) were determined based on signal-to-noise [25], by relating extrapolated response (linear regression "through origin", y intercept set to 1) to the standard deviation of blank samples (σ blank ) without heparin. The limit of detection (LOD) was calculated as LOD = 3 σ blank / S (S= slope of response curve, see figure 1 ) and the limit of quantification as LOQ = 10 σ blank / S. Table 1 . σblank, coefficient of determination (r Response of the assays to the low molewcular weight heparin enoxaparin (figure 3) follows similar trends as observed for unfractionated heparin. The decrease of optical signals is more pronounced since in the heparin and enoxaparin solutions of the same potency (expressed in IU/mL), the mass concentration of enoxaparin is significantly higher, and the dye assays respond to mass concentration rather than potency (compare reference [7] ). 
Assay
